Peter Schmid, MD, PhD, on Clinical Implications of New Data on Pembrolizumab Plus Chemotherapy for TNBC

Posted: Monday, January 22, 2024

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses the clinical implications of recent phase III findings from the KEYNOTE-522 trial on the use of pembrolizumab plus chemotherapy for patients with early-stage triple-negative breast cancer, including data on toxicities and overall survival.

---